Search

Your search keyword '"Wyeth -- Mergers, acquisitions and divestments"' showing total 24 results
Start Over Descriptor "Wyeth -- Mergers, acquisitions and divestments" Journal the wall street journal eastern edition
24 results on '"Wyeth -- Mergers, acquisitions and divestments"'

1. Pfizer profit declines 70% on merger, litigation costs

Author

Gryta, Thomas

Subjects
Pfizer Inc. -- Company sales and earnings, Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Cases, Wyeth -- Mergers, acquisitions and divestments, Revenue -- Reports, Revenue -- Forecasts and trends, Sales -- Reports, Sales -- Forecasts and trends, Sales forecasting -- Reports, Stocks -- Prices and rates, Acquisitions and mergers -- Finance, Actions and defenses -- Finance, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Cases, Profit -- Reports, Profit -- Forecasts and trends, Sales analysis, Company earnings/profit, Company acquisition/merger, Company legal issue, Company financing, Market trend/market analysis, Company pricing policy, Lawsuit/litigation, News, opinion and commentary
Published
2010

2. Pfizer wins Prevnar 13 approval, in quick boost from Wyeth deal

Author

Rockoff, Jonathan D.

Subjects
United States. Food and Drug Administration -- Powers and duties, Pfizer Inc. -- Product development, Pfizer Inc. -- Licensing, certification and accreditation, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Licensing, certification and accreditation, Pharmaceutical industry -- Mergers, acquisitions and divestments, Vaccines -- Product development, Vaccines -- Licensing, certification and accreditation, Administrative agencies -- Powers and duties, Acquisitions and mergers, Drug approval, Company acquisition/merger, News, opinion and commentary, Prevnar (Vaccine) -- Product development, Prevnar (Vaccine) -- Licensing, certification and accreditation
Published
2010

3. Pfizer plans to cut R&D by up to $3 billion; drug giant hopes to wring efficiencies from Wyeth purchase; move comes as some rivals boost development budgets

Author

Rockoff, Jonathan D.

Subjects
Pfizer Inc. -- Research, Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Company sales and earnings, Wyeth -- Mergers, acquisitions and divestments, Industrial research -- United States, Industrial research -- Control, Pharmaceutical industry -- Research, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Company sales and earnings, Profit -- Reports, Profit -- Forecasts and trends, Revenue -- Reports, Revenue -- Forecasts and trends, Stocks -- Prices and rates, Acquisitions and mergers, Research and development, Company acquisition/merger, Company earnings/profit, Market trend/market analysis, Company pricing policy, News, opinion and commentary
Published
2010

4. SEC probes transactions in a hunt for inside trades

Author

Strasburg, Jenny and Scannell, Kara

Subjects
United States. Securities and Exchange Commission -- Investigations, Merck & Company Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Mergers, acquisitions and divestments, Schering-Plough Corp. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Administrative agencies -- Investigations, Governmental investigations -- Analysis, Insider trading in securities -- Investigations, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company legal issue, Company acquisition/merger, News, opinion and commentary
Published
2009

5. Pfizer shuts six R&D sites after takeover

Author

Rockoff, Jonathan D.

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Facility closures, Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Facility closures, Layoffs -- Management, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Facility closures, Plant shutdowns, Layoff, Company acquisition/merger, Company business management, News, opinion and commentary
Published
2009

6. U.S. drug companies chase vaccines

Author

Rockoff, Jonathan D. and Loftus, Peter

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Mergers, acquisitions and divestments, CSL Ltd. (Parkville, Victoria) -- Licensing agreements, CSL Ltd. (Parkville, Victoria) -- Mergers, acquisitions and divestments, Crucell N.V. -- Mergers, acquisitions and divestments, Johnson & Johnson -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Marketing, Merck & Company Inc. -- Licensing agreements, Pfizer Inc. -- Mergers, acquisitions and divestments, Solvay S.A. (Brussels, Belgium) -- Subsidiaries, divisions and units, Solvay S.A. (Brussels, Belgium) -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Biological products industry -- Licensing agreements, Biological products industry -- Mergers, acquisitions and divestments, Biotechnology industry -- Mergers, acquisitions and divestments, Chemical industry -- Mergers, acquisitions and divestments, Chemical industry -- Subsidiaries, divisions and units, Herbicides -- Mergers, acquisitions and divestments, Herbicides -- Subsidiaries, divisions and units, Pesticides industry -- Mergers, acquisitions and divestments, Pesticides industry -- Subsidiaries, divisions and units, Pharmaceutical industry -- Forecasts and trends, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Product development, Pharmaceutical industry -- Marketing, Pharmaceutical industry -- Intellectual property, Influenza vaccines -- Licensing agreements, Influenza vaccines -- Intellectual property, Influenza vaccines -- Product development, Influenza vaccines -- Marketing, Company licensing agreement, Company acquisition/merger, Company marketing practices, Market trend/market analysis, News, opinion and commentary
Published
2009

7. Pfizer outlines post-Wyeth R&D structure; company splits research on traditional drugs from biologics and strives to retain scientists

Author

Johnson, Avery

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Officials and employees, Pfizer Inc. -- Management, Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Management, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Management, Pharmaceutical research -- Reorganization and restructuring, Acquisitions and mergers, Company acquisition/merger, Company business management, Company restructuring/company reorganization, Company organization, News, opinion and commentary
Published
2009

8. Global M&A hits the skids, and few deal makers see quick rebound

Author

Karnnitschnig, Matthew and Cimilluca, Dana

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Rankings, Wyeth -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Forecasts and trends, Acquisitions and mergers -- Finance, Credit ratings -- Analysis, Economic indicators -- Analysis, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Rankings, Company acquisition/merger, Market trend/market analysis, Company financing, News, opinion and commentary
Published
2009

9. Nissan Motor is planning $1.5 billion sale

Author

Shrivastava, Anusha, Rappaport, Liz, Varghese, Romy, and Blumberg, Deborah Lynn

Subjects
Nissan Motor Company Ltd. -- Securities, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Planning, Acquisitions and mergers -- Finance, Automobile industry -- Securities, Bond issues -- Planning, Corporate bonds -- Planning, Corporate bonds -- Mergers, acquisitions and divestments, Credit market -- Forecasts and trends, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Securities, Stocks -- Prices and rates, Treasury securities -- Prices and rates, Yield (Investments) -- Reports, Corporate divestiture, Automobile Industry, Divestment, Company securities, Company acquisition/merger, Company business planning, Company financing, Market trend/market analysis, Company pricing policy, News, opinion and commentary
Published
2009

10. Drug mergers buck up banks; deals by Pfizer, Merck, others generate fees of roughly $500 million

Author

Moore, Heidi N.

Subjects
CV Therapeutics Inc. -- Mergers, acquisitions and divestments, Genentech Inc. -- Mergers, acquisitions and divestments, Gilead Sciences Inc. -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Mergers, acquisitions and divestments, Roche Holding Ltd. -- Mergers, acquisitions and divestments, Schering-Plough Corp. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Analysis, Acquisitions and mergers -- Economic aspects, Banks (Finance) -- Company sales and earnings, Biological products industry -- Mergers, acquisitions and divestments, Biotechnology industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company acquisition/merger, Company earnings/profit, News, opinion and commentary
Published
2009

11. Foreign capital flees the U.S.; outflow hits record $148.9 billion as China reloads

Author

Zeng, Min, Barkely, Tom, Derby, Michael S., and Geressy, Kellie

Subjects
United States. Department of the Treasury -- Reports, Pfizer Inc. -- Securities, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Credit market -- Forecasts and trends, Foreign investments -- Forecasts and trends, Administrative agencies -- Reports, Pharmaceutical industry -- Securities, Pharmaceutical industry -- Mergers, acquisitions and divestments, Treasury securities -- Prices and rates, Yield (Investments) -- Reports, Company securities, Company acquisition/merger, Market trend/market analysis, Company pricing policy, News, opinion and commentary
Published
2009

12. Drug firms bet big on high-risk deals

Author

Winslow, Ron and Johnson, Avery

Subjects
Genentech Inc. -- Mergers, acquisitions and divestments, Genentech Inc. -- Company sales and earnings, Merck & Company Inc. -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Company sales and earnings, Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Company sales and earnings, Roche Holding Ltd. -- Finance, Roche Holding Ltd. -- Mergers, acquisitions and divestments, Roche Holding Ltd. -- Company sales and earnings, Schering-Plough Corp. -- Mergers, acquisitions and divestments, Schering-Plough Corp. -- Company sales and earnings, Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Company sales and earnings, Biotechnology industry -- Mergers, acquisitions and divestments, Biotechnology industry -- Company sales and earnings, Drugs -- Product development, Drugs -- Intellectual property, Drugs -- Marketing, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Intellectual property, Pharmaceutical industry -- Product development, Acquisitions and mergers, Patents, Patent/copyright issue, Company acquisition/merger, Company earnings/profit, Company financing, Company marketing practices, News, opinion and commentary
Published
2009

13. For drug deals, small is beautiful

Author

Jannarone, John

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Securities, CV Therapeutics Inc. -- Mergers, acquisitions and divestments, Gilead Sciences Inc. -- Mergers, acquisitions and divestments, Johnson & Johnson -- Securities, Johnson & Johnson -- Mergers, acquisitions and divestments, Pfizer Inc. -- Company sales and earnings, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Analysis, Biological products industry -- Mergers, acquisitions and divestments, Business losses -- Analysis, Market capitalization -- Analysis, Pharmaceutical industry -- Forecasts and trends, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Mergers, acquisitions and divestments, Stocks -- Prices and rates, Company securities, Company acquisition/merger, Company earnings/profit, Market trend/market analysis, Company pricing policy, News, opinion and commentary
Published
2009

14. Drug-industry shakeout hits small firms hard; another wave of acquisitions is likely as companies worry about their drug pipelines and health-care change

Author

Johnson, Avery and Winslow, Ron

Subjects
Genentech Inc. -- Negotiation, mediation and arbitration, Genentech Inc. -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Mergers, acquisitions and divestments, Roche Holding Ltd. -- Mergers, acquisitions and divestments, Roche Holding Ltd. -- Negotiation, mediation and arbitration, Schering-Plough Corp. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Forecasts and trends, Biotechnology industry -- Negotiation, mediation and arbitration, Biotechnology industry -- Mergers, acquisitions and divestments, Drugs -- Marketing, Drugs -- Product development, Drugs -- Research, Health care reform -- Economic aspects, Health care reform -- Analysis, Medical policy -- Analysis, Pharmaceutical industry -- Forecasts and trends, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Negotiation, mediation and arbitration, Pharmaceutical research -- Forecasts and trends, Company acquisition/merger, Market trend/market analysis, Company marketing practices, News, opinion and commentary
Published
2009

15. Wyeth vaccines also lured Pfizer; special court, 1986 act transformed sector into attractive product line

Author

Johnson, Avery

Subjects
Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Product information, Pfizer Inc. -- Mergers, acquisitions and divestments, Actions and defenses -- Analysis, Children -- Health aspects, Courts -- United States, Courts -- Powers and duties, Courts -- Analysis, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Cases, Pharmaceutical industry -- Product information, Vaccines -- Cases, Vaccines -- Complications and side effects, Vaccines -- Marketing, Lawsuit/litigation, Company acquisition/merger, Company legal issue, Company marketing practices, Company product acquisition, Product marketing strategy, News, opinion and commentary
Published
2009

16. Lilly CEO says he is open to animal-health deal

Author

Rockoff, Jonathan D.

Subjects
Eli Lilly and Co. -- Officials and employees, Eli Lilly and Co. -- Company sales and earnings, Eli Lilly and Co. -- Securities, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Business losses -- Reports, Chief executive officers -- Beliefs, opinions and attitudes, Pharmaceutical industry -- Officials and employees, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Securities, Pharmaceutical industry -- Mergers, acquisitions and divestments, Stocks -- Prices and rates, Acquisitions and mergers, Company earnings/profit, Company securities, Company acquisition/merger, Company pricing policy, News, opinion and commentary
Published
2009

17. The Pfizer drug warning

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Intellectual property, Pfizer Inc. -- Company sales and earnings, Wyeth -- Mergers, acquisitions and divestments, Anticholesteremic agents -- Intellectual property, Anticholesteremic agents -- Marketing, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Intellectual property, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical research -- Innovations, Pharmaceutical research -- Forecasts and trends, Acquisitions and mergers -- Analysis, Patents, Company marketing practices, Patent/copyright issue, Company acquisition/merger, Company earnings/profit, Market trend/market analysis, News, opinion and commentary, Lipitor (Medication) -- Marketing, Lipitor (Medication) -- Intellectual property
Published
2009

18. Pfizer deal to buy Wyeth leaves doubts

Author

Rockoff, Jonathan D. and Wang, Shirley S.

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Company sales and earnings, Pfizer Inc. -- Securities, Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Company sales and earnings, Wyeth -- Securities, Acquisitions and mergers -- Planning, Acquisitions and mergers -- Evaluation, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Securities, Profit -- Analysis, Stocks -- Prices and rates, Company business planning, Company acquisition/merger, Company earnings/profit, Company securities, Company pricing policy, News, opinion and commentary
Abstract

Pfizer Inc.'s planned $68 billion deal to acquire Wyeth has some analysts in doubt. They say that problems such as the $12.4 billion annual revenue loss caused by the patent expiry on Pfizer's best-selling anti-cholesterol drug Lipitor will not be solved by the deal.

Published
2009

19. Why banks will lend billions for Pfizer deal

Author

Karntischnig, Matthew and Moore, Heidi N.

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Planning, Acquisitions and mergers -- Finance, Banks (Finance) -- Investments, Pharmaceutical industry -- Mergers, acquisitions and divestments, Syndicates (Finance) -- Investments, Bank loans, Company business planning, Company financing, Company investment, Company acquisition/merger, News, opinion and commentary
Abstract

Pfizer Inc. is to acquire Wyeth for $68 billion, and will finance the deal with $22.5 billion in fresh debt, with the remainder in stock and cash. The financing is from a syndicate of banks.

Published
2009

20. Pfizer treatment is no cure

Author

Jannarone, John

Subjects
Pfizer Inc. -- Company sales and earnings, Pfizer Inc. -- Intellectual property, Pfizer Inc. -- Marketing, Pfizer Inc. -- Securities, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Company sales and earnings, Acquisitions and mergers -- Negotiation, mediation and arbitration, Anticholesteremic agents -- Marketing, Anticholesteremic agents -- Intellectual property, Market capitalization -- Analysis, Pharmaceutical industry -- Company sales and earnings, Pharmaceutical industry -- Intellectual property, Pharmaceutical industry -- Marketing, Pharmaceutical industry -- Securities, Pharmaceutical industry -- Mergers, acquisitions and divestments, Profit -- Analysis, Profit -- Forecasts and trends, Stocks -- Prices and rates, Lapse (Law), Patents, Company securities, Company acquisition/merger, Company earnings/profit, Company marketing practices, Market trend/market analysis, Company pricing policy, Patent/copyright issue, News, opinion and commentary
Published
2009

21. Wyeth, Pfizer rise on merger rumblings; GE slides

Author

Curran, Rob

Subjects
General Electric Co. -- Securities, Pfizer Inc. -- Securities, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Securities, Wyeth -- Mergers, acquisitions and divestments, Dow Jones Industrial Average (Index) -- Reports, Nasdaq 100 Index (Index) -- Reports, Electrical equipment and supplies industry -- Securities, Electrical equipment and supplies industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Securities, Pharmaceutical industry -- Mergers, acquisitions and divestments, Stock markets -- Reports, Stock price indexes -- Reports, Stocks -- Prices and rates, Blue chip stocks -- Prices and rates, Economic indicators -- Analysis, Company securities, Company acquisition/merger, Company pricing policy, Stock market, News, opinion and commentary
Published
2009

22. Pfizer nears giant drug deal

Author

Karnitschnig, Matthew and Rubenstein, Sarah

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments, Pfizer Inc. -- Securities, Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Securities, Stocks -- Prices and rates, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Securities, Acquisitions and mergers -- Planning, Anticholesteremic agents -- Intellectual property, Anticholesteremic agents -- Marketing, Company acquisition/merger, Company securities, Company business planning, Company marketing practices, Company pricing policy, News, opinion and commentary, Lipitor (Medication) -- Marketing, Lipitor (Medication) -- Intellectual property
Abstract

As its anti-cholesterol drug Lipitor faces the expiry of its patent protection in 2011, Pfizer Inc. is looking to expand its reach in other areas, and has completed a deal to acquire Wyeth for $65 billion to $70 billion. Lipitor sales represents about one-quarter of Pfizer's total sales and brought in $12.7 billion in 2008.

Published
2009

23. Pfizer in talks to buy Wyeth

Author

Karnitschnig, Matthew and Rockoff, Jonathan D.

Subjects
Pfizer Inc. -- Negotiation, mediation and arbitration, Pfizer Inc. -- Mergers, acquisitions and divestments, Wyeth -- Negotiation, mediation and arbitration, Wyeth -- Mergers, acquisitions and divestments, Acquisitions and mergers -- Negotiation, mediation and arbitration, Pharmaceutical industry -- Negotiation, mediation and arbitration, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company acquisition/merger, News, opinion and commentary
Published
2009

24. On a hunt, Wyeth seeks Dutch maker of vaccines

Author

Cimilluca, Dana and Whalen, Jeanne

Subjects
Crucell N.V. -- Negotiation, mediation and arbitration, Crucell N.V. -- Mergers, acquisitions and divestments, Crucell N.V. -- Securities, Wyeth -- Negotiation, mediation and arbitration, Wyeth -- Mergers, acquisitions and divestments, Wyeth -- Securities, Acquisitions and mergers -- Planning, Acquisitions and mergers -- Negotiation, mediation and arbitration, Biotechnology industry -- Negotiation, mediation and arbitration, Biotechnology industry -- Mergers, acquisitions and divestments, Biotechnology industry -- Securities, Pharmaceutical industry -- Negotiation, mediation and arbitration, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Securities, Stocks -- Prices and rates, Company acquisition/merger, Company securities, Company business planning, Company pricing policy, News, opinion and commentary
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results